Back to Search
Start Over
BOC.04.2: TWO-YEAR EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLOWING 104 WEEKS OF CONTINUOUS TREATMENT: INTERIM RESULTS FROM THE LUCENT-3 OPEN-LABEL EXTENSION STUDY.
- Source :
- Digestive & Liver Disease; 2024 Supplement 2, Vol. 56, pS121-S122, 2p
- Publication Year :
- 2024
Details
- Language :
- English
- ISSN :
- 15908658
- Volume :
- 56
- Database :
- Supplemental Index
- Journal :
- Digestive & Liver Disease
- Publication Type :
- Academic Journal
- Accession number :
- 176502530
- Full Text :
- https://doi.org/10.1016/S1590-8658(24)00389-X